Eli Lilly's Foundayo Clears Key Cardiac Hurdle, Paving Path for Diabetes Approval

Eli Lilly's oral GLP-1 drug Foundayo shows cardiovascular safety and weight loss in Phase 3 trial, directly addressing FDA concerns and setting up a potential 2026 launch.

Positive late-stage trial results for Eli Lilly's oral GLP-1 drug Foundayo have directly addressed lingering FDA safety concerns, potentially accelerating its path to a diabetes market launch. The company announced on Thursday that its ACHIEVE-4 study met its primary goal, demonstrating the pill's cardiovascular safety profile.

The Phase 3 trial, which enrolled over 2,700 participants with type-2 diabetes and elevated cardiovascular risk across 15 countries, showed Foundayo (orforglipron) was non-inferior to insulin glargine in preventing major adverse cardiac events. The observed risk for events like heart attack and stroke was 16% lower in the Foundayo group. An exploratory analysis also indicated a substantial 57% reduction in all-cause mortality, though this finding requires further confirmation.

Beyond safety, the drug's efficacy profile was robust. Patients on Foundayo achieved greater reductions in HbA1c levels and lost an average of 8.8% of their body weight over 104 weeks. In stark contrast, those on insulin therapy gained approximately 1.7% over the same period.

These results arrive at a critical regulatory juncture. The U.S. Food and Drug Administration had recently requested additional long-term data on liver and cardiovascular risks, specifically tied to Foundayo's prior accelerated approval for obesity. Lilly now states the ACHIEVE-4 study revealed no signals of drug-induced liver injury, a point analysts view as a direct response to the agency's queries.

Buoyed by the data, Eli Lilly plans to submit a supplemental New Drug Application for the type-2 diabetes indication by the end of the second quarter. The company intends to use a priority review voucher, which could enable a market launch in the latter half of 2026.

The clinical milestone coincides with other strategic moves. Separately, Lilly is bolstering its oncology pipeline through the acquisition of CrossBridge Bio for up to $300 million. The deal brings in an antibody-drug conjugate platform, with a TROP2-targeted asset called CBB-120 slated for an Investigational New Drug application this year.

Investor focus now shifts to the company's upcoming first-quarter earnings report on April 30. Analysts anticipate earnings per share of $7.52, representing a surge of over 125% year-over-year. The market will also scrutinize updates on GLP-1 manufacturing capacity, following Lilly's recent multi-billion dollar investments in Asian production facilities.

Despite the positive clinical news, Lilly's shares have faced pressure, recently trading around 774.50 EUR. This places them roughly 15% below their year-start level and 19% off a 52-week high of 959.50 EUR, reflecting earlier regulatory uncertainties. The stock retains strong analyst support, however, with Morgan Stanley maintaining an "Overweight" rating and a $1,327 price target, and Bank of America seeing a fair value of $1,294.

Foundayo is poised to fuel Lilly's already dominant position in the metabolic disease market. The company commands a 60% share of the U.S. weight-loss drug sector, with products Zepbound and Mounjaro generating over $11 billion in revenue last quarter and contributing to a 43% jump in total company revenue to above $19 billion. RBC Capital forecasts Foundayo could bring in $1.7 billion this year, with long-term peak sales potential reaching $35 billion.